Research Papers:
Matched-pair analysis of survival in patients with poorly differentiated versus well-differentiated glottic squamous cell carcinoma
Metrics: PDF 1853 views | HTML 2761 views | ?
Abstract
Ping Chen1,*, Wenbin Yu2,*, Junwei Huang1, Hongbo Xu1, Guojun Li3,4, Xiaohong Chen1, Zhigang Huang1
1Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China
2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head and Neck surgery, Peking University Cancer Hospital & Institute, Houston, TX 77030, USA
3Department of Head and Neck Surgery, Houston, TX 77030, USA
4Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
*These authors contributed equally to this work and co-first authors
Correspondence to:
Zhigang Huang, email: [email protected]
Xiaohong Chen, email: [email protected]
Keywords: differentiation, laryngeal carcinoma, prognosis, staging, survival
Received: November 18, 2016 Accepted: January 11, 2017 Published: January 20, 2017
ABSTRACT
To compare survival outcomes between patients with poorly differentiated versus well-differentiated glottic squamous cell carcinoma (GSCC). Fifty-five patients with well-differentiated newly diagnosed GSCC were pair-matched to 55 patients with poorly differentiated GSCC according to age, sex, year of diagnosis, overall stage, treatment (surgery type, neck dissection, surgical margin, and chemoradiation), smoking, and alcohol use. Survival analysis was performed using Kaplan-Meier estimates, and matched-pair survival was estimated using the Cox proportional hazards regression model. Patients with well-differentiated GSCC had significantly better overall survival (OS) (P = 0.001), disease-specific survival (DSS) (P < 0.001), and disease-free survival (DFS) (P = 0.003) than patients with poorly differentiated GSCC. Moreover, matched-pair analysis indicated that increased differentiation was associated with a significantly reduced risk of overall death (HR, 0.18; 95% confidence interval [CI], 0.07–0.46), death owing to disease (HR, 0.16; 95% CI, 0.05–0.45), and disease recurrence (HR, 0.17; 95% CI, 0.07–0.41), and these risks were reduced approximately 4-fold, 3.7-fold, and 9-fold, respectively, after adjustment for cancer-associated variables. Survival differed significantly between the well-differentiated and poorly differentiated GSCC patients after adjustment for cancer prognosis-associated variables. Thus, identifying potential differences in the molecular characteristics between these two groups of patients would help to further stratify these patients and ensure appropriate individualized treatment decisions. Basing treatment strategies on the level of differentiation may improve survival.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14772